GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pfizer Inc (MIL:1PFE) » Definitions » Cyclically Adjusted Price-to-FCF

Pfizer (MIL:1PFE) Cyclically Adjusted Price-to-FCF : 7.32 (As of Jun. 05, 2025)


View and export this data going back to 2023. Start your Free Trial

What is Pfizer Cyclically Adjusted Price-to-FCF?

As of today (2025-06-05), Pfizer's current share price is €20.565. Pfizer's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €2.81. Pfizer's Cyclically Adjusted Price-to-FCF for today is 7.32.

The historical rank and industry rank for Pfizer's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

MIL:1PFE' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 7.09   Med: 14.49   Max: 21.47
Current: 7.58

During the past years, Pfizer's highest Cyclically Adjusted Price-to-FCF was 21.47. The lowest was 7.09. And the median was 14.49.

MIL:1PFE's Cyclically Adjusted Price-to-FCF is ranked better than
93.85% of 325 companies
in the Drug Manufacturers industry
Industry Median: 31.58 vs MIL:1PFE: 7.58

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Pfizer's adjusted free cash flow per share data for the three months ended in Mar. 2025 was €0.287. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is €2.81 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pfizer Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Pfizer's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pfizer Cyclically Adjusted Price-to-FCF Chart

Pfizer Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.25 20.86 15.98 9.33 8.77

Pfizer Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.97 9.35 9.55 8.77 8.21

Competitive Comparison of Pfizer's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, Pfizer's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pfizer's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pfizer's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Pfizer's Cyclically Adjusted Price-to-FCF falls into.


;
;

Pfizer Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Pfizer's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=20.565/2.81
=7.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Pfizer's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.287/134.9266*134.9266
=0.287

Current CPI (Mar. 2025) = 134.9266.

Pfizer Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.546 100.684 0.732
201509 0.670 100.392 0.900
201512 0.622 99.792 0.841
201603 0.217 100.470 0.291
201606 0.450 101.688 0.597
201609 0.624 101.861 0.827
201612 0.818 101.863 1.084
201703 0.188 102.862 0.247
201706 0.406 103.349 0.530
201709 0.596 104.136 0.772
201712 0.881 104.011 1.143
201803 0.210 105.290 0.269
201806 0.492 106.317 0.624
201809 0.672 106.507 0.851
201812 0.595 105.998 0.757
201903 0.166 107.251 0.209
201906 0.316 108.070 0.395
201909 0.619 108.329 0.771
201912 0.574 108.420 0.714
202003 0.433 108.902 0.536
202006 0.490 108.767 0.608
202009 0.239 109.815 0.294
202012 0.699 109.897 0.858
202103 0.591 111.754 0.714
202106 1.573 114.631 1.851
202109 1.516 115.734 1.767
202112 0.754 117.630 0.865
202203 0.930 121.301 1.034
202206 1.229 125.017 1.326
202209 0.907 125.227 0.977
202212 1.246 125.222 1.343
202303 0.012 127.348 0.013
202306 -0.343 128.729 -0.360
202309 0.439 129.860 0.456
202312 0.676 129.419 0.705
202403 0.062 131.776 0.063
202406 -0.394 132.554 -0.401
202409 0.958 133.029 0.972
202412 0.972 133.157 0.985
202503 0.287 134.927 0.287

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pfizer  (MIL:1PFE) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Pfizer Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Pfizer's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pfizer Business Description

Industry
Address
66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Headlines

No Headlines